The Extended Iterative Optimization Technology (EIOT) method is proposed as an extension to Muteki's [I&ECR 2013;52 (35):12258-12268] Iterative Optimization Technology to address deviations from Beer-Lambert's law in powders. The new method estimates the apparent spectrum for the pure species, rather than using the measured spectrum and augments Beer-Lambert's law with a bilinear term to capture the signature and strength of the nonchemical interferences. The proposed method has exhibited acceptable performance in spite of using a lean data set to estimate its parameters. The method provides robust and coherent estimates within the physical boundaries of the system and exhibits robustness to instrument transfer. The lean effort needed to build the EIOT method positions it as an attractive option in early stages of pharmaceutical drug product development. Its robustness to distinguish chemical from nonchemical signals implies a potential to lower the total cost of ownership for an EIOT-based solution in manufacturing.
Introduction
A first wave in the modernization of pharmaceutical product development and manufacturing was driven by guidance documents and initiatives introduced by the Food and Drug Administration (FDA) in the early 2000s. 1 Among these, the Process Analytical Technology (PAT) initiative 2 is perhaps one of the most impactful ones in the way it triggered companies to invest in new technology. The introduction of this guidance encourages the analysis, design, and control of the manufacturing process through timely measurements of the key quality attributes of the product. A historical perspective on the development of the PAT initiative and its initial influence to industry and regulatory practices during the following years after rollout is discussed by Hinz. 3 Fourteen years after the guidance was issued, the implementation of "PAT at some level" is now a common practice among pharmaceutical development and manufacturing with diverse applications across the product lifecycle. 4 This enthusiastic response from industry in implementing new technology 5 finds its counterpart in the Emerging Technology Team (ETT) launched by the FDA's Office for Pharmaceutical Quality in 2015. 6 A second wave of modernization in the sector is characterized by the introduction of continuous processes for the manufacture of medicines. 7 The introduction of continuous manufacturing further energized the PAT field due to the need to monitor the process at a higher frequency relative to its batch counterpart. The application of PAT for continuous processes has particularly flourished in the manufacture of drug product, where applications have been reported in multiple platforms from spray drying, to wet and dry granulation, to direct compression. 8 From the multiple platforms for drug product manufacture, continuous direct compression has been successfully applied to the development and manufacture of drug product 9 and remains a route of preference due to its simplicity and small footprint. The various materials are continuously fed at the top of the unit and moved downward by gravity through a mixing unit and into the tablet press. Mixing in the system occurs by forced convection as well as by dispersion as the material moves from top to bottom and is not limited to occur exclusively in the mixing unit but throughout the length of transit. 10 The last free volume where mixing occurs is the feed-frame of the tablet press; the mixing of the powders is incomplete before this point. Studies have shown that the concentration of drug as observed in the feed-frame is practically the same as in the tablet. 11 Hence, the development of PAT solutions to estimate the concentration of drug in the feed-frame has received special attention from researchers.
Ward et al. 12 reported the performance of a near-infrared (NIR) probe installed in the feed-frame of a Kilian T-100 (IMA, Koln, Germany) tablet press, mainly seeking to determine the sensitivity of the instrument and the interference of physical factors. Their study found initial optimistic results correlating the signal reported by the NIR probe and the measured concentration of drug in the tablet. Mateo-Ortiz et al. 13 studied a similar system using a Fette 3090 (Fette Compacting GmbH, Germany) tablet press; their study found that physical effects brought by operating conditions like throughput and the speed of the feeder wheels were important and affected the NIR signal. Wahl et al.
14 studied a NIR in the feed-frame of a Kilian Synthesis 500 (Kilian GmbH & Co, Germany) tablet press; their study corroborated the findings of previous work and raises interesting questions regarding the formal use of the results from high frequency methods as they contrast with the traditional ones that rely on withdrawing tablets and laboratory testing. In their work, the authors question that the methods and rules built for infrequent sampling scenarios would apply to high frequency sampling scenarios; these questions remain a point of debate as of today. Sasic et al. 15 worked on a similar system and reports the dominant effect of a bias (i.e., baseline shift) along the wavelength axis. The authors attempt to manage this bias with preprocessing in a univariate approach. Additional studies can also be found using multiple probes into the feed frame 16, 17 ; these studies look into the usage of light induced fluorescence, near-infrared and an RGB camera. These multiprobe studies are yet inconclusive on the advantages of having multiple signals and rather point to the practical benefits of having different instruments available to study a system.
Most of the work discussed utilizes a partial-least squares (PLS) approach to regress the spectral data to the concentration of drug in the powder. In our opinion at the point in time this article is written, there is little doubt that among pharmaceutical practitioners, PLS is currently the method of choice in PAT applications. The knowledge to develop these calibrations and use them in pharmaceutical applications is common to the point that regulatory agencies have produced guidance documents for them. 18 Among the expectations and requirements to build these PAT solutions and deploy them in a pharmaceutical manufacturing setting, the long-term lifecycle strategy for the maintenance of the underlying regression model is perhaps the most challenging from a practitioner's standpoint. This is due to the potential of turning the maintenance of the instrument and the model into a time-consuming activity for the manufacturing personnel, such that the cost of maintenance now surpasses the business benefits of the deployed PAT solution.
The total cost of ownership (development and maintenance) is not to be underestimated and has been recognized itself as an area of research by some academics. 19 This is a particularly difficult aspect as the development of a model that would potentially require less maintenance will have to account for variations and disturbances not typically seen at the development scale. Introducing these sources of variation experimentally may require large quantities of drug and incurred cost for use of a large-scale facility 11 ; eventually raising the cost of development for the model. This high cost of model development is of course invested at risk before the drug becomes approved for commercial manufacture, and increasing overall cost of development for a new drug is opposite to current trends in the business.
Several solutions have been proposed to minimize some aspects of the cost of maintenance for a PAT application. Among these, Nakagawa et al. 20 propose the use of the Locally Weighted PLS 21 method as a way to reasonably adapt the model to the new sample and correct for small rotational nonlinearities that might be present across the range of calibration. These methods remain an attractive solution for small corrections to the online predictions. The authors conclude their method remains attractive to diminish modelmaintenance but does not address the cost of model development. In their conclusion, the authors point to the work from Muteki et al. 22 as an alternative method with leandevelopment requirements.
The Iterative Optimization Technology (IOT) method is presented by Muteki et al. 22 as an alternative calibration-free approach to the translation of spectroscopic data into concentration predictions. This work is disruptive in nature since it challenges the need for a regression model and poses the problem as an optimization one (Eq. 1). In this formulation, the pure spectra of the n species (s n ) are assumed to be known. Driven by Beer-Lambert's law the problem is formulated as a quadratic programming optimization problem (Eq. 1). The solution of this problem is the molar fraction of the n components in the new sample (r mole ) given the measured spectra for the new sample (d new ). This optimization calculation is constrained to fulfill the need of the summation of mole-fractions to add to unity.
Muteki et al. present optimistic results for mixtures in solution and encouraging preliminary results using a powder mixture of three species. For mixtures that deviate from BeerLambert's, they propose a nonlinear approach where the signal at each wavelength is preprocessed with a box-cox transform. 22 IOT has two major drawbacks driven by the assumption of Beer-Lambert's: first, the obtained fractions are in molar basis and given the polymeric nature of some common excipients translating the molar ratios into mass ratios can prove to be difficult (mass fractions are needed in practice); Second, the assumption that Beer-Lambert's law applies in powder systems is questionable in all wavelength regions due to scattering effects and the interference of nonchemically related factors. These deviations have been reported either as biases (Sasic et al. 15 ) or as "nonlinear" effects since these are deviations from the linear mathematical form represented by BeerLambert's. A research group at University of Tokyo led by Prof. Kimito Funatsu has proposed the use of their genetic algorithm (GA) approaches to variable selection 23 as an extension to the IOT method. 24 Their approach uses the GA to identify wavelengths in the spectra that follow Beer-Lambert's law and hence improve the predictive results from IOT. They have also proposed to change the mathematical formulation adding a nonlinear term such that the spectrum of the mixture is a function of a linear and a nonlinear term (Eq. 2). This approach implies the additional estimation of the nonlinear spectral signatures (s nonlinear,n ) and the order (p n ) of the nonlinear component per ingredient. None of these proposals addresses the fact that the estimate of r n is a molar fraction.
In this work, we propose the Extended Iterative Optimization Technology (EIOT) method as an attractive alternative to the practitioner offering acceptable performance with lean development efforts and low cost of ownership. Our contribution differs from the above discussed proposals in two ways: (i) we use data from mixtures of known composition to estimate the pure spectrum of the individual components such that Beer-Lambert holds and such that the estimate is scaled to a mass fraction basis; and (ii) we extend the IOT method with an augmented term that accounts for the nonchemical interferences assuming these have a common signature that exhibits itself with variable strength in a sample by sample basis.
The rest of the article is organized as follows: we discuss the EIOT method and the mathematics behind it; we illustrate the various features of the method with a simulated spectral data set. The third section presents multiple case studies with actual scenarios from our business. Example results from the application of EIOT in the early stages of pharmaceutical development are discussed; our initial thoughts on diagnostics are given, followed by our concluding remarks.
Extended Iterative Optimization Technology (EIOT)
IOT is proposed as a calibration-free approach since the parameters (i.e., the pure spectra for each species) needed to estimate concentration of a new sample are not estimated but measured. In this work we propose to go back to the usage of a data set of spectra collected at known concentrations, with the advantage of requiring a much leaner data set that than required for a typical regression solution. From this data, we propose to estimate a set of modified pure spectra for each species such that the deviations from Beer's law are minimized and the relationship between mixture spectra and pure is on a mass basis, not a molar one. Once these estimations for the pure spectra are obtained, we propose an augmentation to Beer's to accommodate for the nonchemical interferences, assuming they share a common signal, but affect each sample with different strength. Once the estimated pure spectra and the signal of the nonchemical interferences are identified, the method proceeds as a linearly constrained quadratic optimization, similar to the IOT one. As with the original IOT, our approach remains drastically different from the regression one as it solves an optimization problem on a sample to sample basis; instead of using a fixed set of regression coefficients to calculate the mass fractions.
In the IOT approach, the underlying model that relates powder mixture to spectra is given by Eq. 3, whered M is the estimation of the measured spectrum from a mixture (vector of λ wavelengths, λ × 1), S is the matrix of pure component spectra of the n species (λ × n) and r mole is the vector of mole fractions for each species (n × 1). IOT uses an optimization formulation to find r mole , such that the error between the predicted spectrum for the mixture and the measured one is minimized (Eq. 1) for every new sample.
In EIOT, we propose to extend the IOT inner model, augmenting it with a linear term to consider all the nonchemical interferences observable in a given sample. This extension is shown in Eq. 4, whereŜ 0 (λ × n) is an estimation of the pure component spectra for each species scaled to a mass fraction basis; r (n × 1) is a vector of mass fractions for each species, s I (λ × 1) is a vector corresponding to the signal of the average nonchemical interference and r I is a scalar representing the strength of the interference as observed in the sample (r I is not an element of r).d
The linearly constrained quadratic programming problem solved in real-time by EIOT is given in Eq. 5; the optimal solution to this problem yields an estimation of the mass fractions for each observable species (r) and the strength of the interference for the sample (r I ). Notice in this formulation the scalar r I remains unconstrained. The steps to estimateŜ 0 , s I , and r I are discussed below.
Estimation of pure spectra for each speciesŜ 0 Define D M as a set of i samples of measured spectra from a powder mixture, consisting of λ columns each; where the vector of mass fractions (r) of each species (n) for each sample (i) is known. A modified expression mimicking Beer-Lambert that relates mixture spectra with pure spectra of the species through a mass-fraction based relation is given in matrix form in Eq. 6.
Where D M is an i × λ matrix, C is an i × n matrix composed of the r vectors of the known mass fraction for each sample (i) (Eq. 7), and S 0 is an n × λ matrix of the pure component spectra for each species scaled by the molecular weight of the corresponding species and the reciprocal of the density of the mixture such that relationship to D M is mass-fraction based.
An estimation of S 0 from this data by least squares can be obtained by Eq. 8 under the assumption that C T C is invertible.
The estimation ofŜ 0 is possible given a data set with enough information about the changes in the mixture spectra as it varies with the mass fraction of each species in the powder mixture.Ŝ 0 hence cannot be estimated for species whose mass fraction is 0 because the corresponding element in the main diagonal of the C T C matrix will be 0 and C T C is not invertible; or for species whose concentration change is proportional to that of another. These linear dependencies introduce a rank deficiency in C which makes the inversion of C T C infeasible. This estimation is also not possible if the mixture spectra exhibits no change with respect to the mass fraction of that species (i.e., there is no signal in that range of wavelengths for such species).
Generating the data set needed for the estimation ofŜ 0 in a continuous manufacturing line for a solid oral drug product is relatively inexpensive and easily obtained by adjusting the setpoints of the feeders in the system and waiting for steady-state to be reached and maintained. The only data used are the spectra sampled at steady-state, where the composition of the blend is known. Several set-point changes will be required to produce data that excites the composition of every species of interest in the powder mixture. Highly informative data are needed in any estimation problem using ordinary least squares (Eq. 8). Our proposal is to use the corners of the compositional space which provides the maximum signal possible; this result in at least two samples (high and low concentration) for each species to be resolved. A broader discussion around the design of experiments for mixture applications can be found in the work by Eriksson and collaborators. 26 From the perspective of the practitioner, in early stages of pharmaceutical process development and clinical manufacture, one could potentially be interested solely in resolving the concentration of the active pharmaceutical ingredient (API) in the blend. Resolving the concentration of each inactive material might be of interest only as the development cycle continues into the later stages of technology transfer to commercial manufacturing facilities.
Estimation of s I
Our observation of spectral residuals after removing the portion explained by Beer-Lambert's law (Figure 1 ) led us to postulate that the measured spectra matrix (D M ) can be decomposed into two contributing portions: the chemically relevant one (first term in Eq. 4) and a nonchemical interference (second term in Eq. 4).
OnceŜ 0 is known, the chemically relevant portion of D M can be estimated and removed from the data (Eq. 9), resulting in what we call the "nonchemical interferences" portion (ε ch ). Upon examination of these residuals for multiple cases, we have come to observe that there is a pattern in these residuals. Different patterns in the residual spectra seem to correspond to process conditions such as mass flow. Figure 1 illustrates an example of this. In the left plot of Figure 1 , four patterns are evident (red, blue, cyan, and magenta lines), where subsets mirror each other in the y-axis (blue mirrors magenta, red mirrors cyan). The right plot of Figure 1 shows the absolute value of the same information where now two distinct patterns can be recognized: cyan and magenta groups.
Visual analysis of the right plot in Figure 1 can lead to the choice of a pattern to represent the "signature" of the interferences (black line in Figure 1 plot on the right). It is postulated that this same interference occurs in all samples but with different strength. This led us to propose that the nonchemical
exhibits itself in each sample (Eq. 10). A simple way to carry out this factorization is to calculate s I as the column wise mean of the absolute value of a subset of observations that clearly exhibit this interference ε ch (Eq. 11). The calculation of r I for the training set from here is trivial. Although the factorization of ε ch clearly has an infinite number of possible solutions, the approach we suggested has resulted in encouraging performance in all the case studies analyzed so far. An alternate approach to calculate s I is to perform singular value decomposition (SVD) on ε ch and use the eigenvector corresponding to the largest eigenvalue as s I .
In summary, the sequence of operations to estimateŜ 0 and s I is as follows:
i. Preprocess spectra as deemed necessary ii. EstimateŜ 0 using Eq. 8. iii. Calculate the nonchemical interferences (ε ch ) with Eq. 9 iv. Identify s I with either Eq. 11, or using the largest eigenvector from an SVD decomposition of ε ch
A Simulated Example
A simulated data set was created to illustrate the performance of the EIOT method. These data are built as follows. First, we defined six independent and mostly nonoverlapping peaks; intended to represent the pure spectra of six species (A to F), spectra for species D and E have a strong overlap Figure 1 . Example of nonchemical interferences in spectra collected in a continuous direct compression line.
[Color figure can be viewed at wileyonlinelibrary.com] (Figure 2a) . Using a flowsheet model of a continuous direct compression system, 10 a simulation was performed to generate the concentration curves (Figure 2b ) obtained, when the material feeders are switched off one by one, compensating the mass flow into the system with the feed rate of the major filler excipient. Excipient B has the lowest nominal mass fraction in the blend, while excipient C has the largest. The time profiles of the concentrations for species A through F and their defined peaks were used to create the simulated clean spectra for the mixture (Figure 2c) . A signature for the nonchemical interferences was defined ( Figure 3 ) and randomly distributed intensity values for the nonchemical interference were generated for each observation. The multiplication of the intensity by the before-defined signature produces the nonchemical interference for each observation and this was added to the clean mixture spectra resulting in the data in Figure 2d .
The data set was partitioned taking one observation out of every two into an estimation set and a test set. The method described in the previous section is applied to the estimation set; Figure 3 illustrates the true signature of the nonchemical interferences against the one identified by the method (s I ). In spite of the overlapping peaks, the low concentration of one of the excipients and the noise added to the data, the method is still able to recover the pattern used to generate the nonchemical interferences. [Color figure can be viewed at wileyonlinelibrary.com] Figure 3 . True vs. estimated structure for the nonchemical interferences in the simulated spectra. Figure 4 illustrates the results from applying the obtained EIOT model to the test data set, as expected, the species with the lower nominal concentrations in the blend (species B and E) exhibit the largest relative errors, while the species with larger nominal concentrations exhibit the lowest relative error (species A and C). Linearity in this case is rigorously imposed on these curves by the explicit formulation of Beer-Lambert's law constrained by the summation of the mass ratios (Eq. 5).
A calculation of signal-to-noise ratio is obtained for these data by quantifying the signal (per species) as the standard deviation of the clean mixture spectra at the center of the corresponding peak and dividing this by the total variance of the noise added which is known in this case. A summary of the obtained error for the testing set is given in Table 1 . It can be observed that the signal-to-noise for species B is less than 1 (0.88). That is, the magnitude of the noise in the spectra is actually larger than the signal from this species; and yet the obtained error, in percentage against nominal is only 2.6%.
Conversely, a species with a large signal to noise ratio (like C for example) has a very small error of 0.06%.
This data set is of course simulated and the results in table 1 do not provide any form of proof or demonstration regarding the performance of the method in a realistic scenario. The results in Table 1 confirm that the calculation sequence provided in the second section is a way to obtain good estimates ofŜ 0 and s I , such that the mass fractions of the species can be correctly calculated in spite of noise and varying levels of nonchemical interferences. The data used in this simulated example are available as supporting additional information. The application of the method to three real pharmaceutical applications is discussed next.
Case Studies
The three case studies reported here were collected using either near infrared (NIR) spectroscopy or Raman spectroscopy at the feed frame of a tablet press from the continuous direct compression process at Eli Lilly and Company. Both spectroscopic tools were deployed in the reflectance mode with collection frequency of every 2 s. The NIR spectrometer and probe was a Prozess 611 NIR Monitoring System (Prozess Technologies, St. Louis, MO) consisting of a tungsten-halogen lamp for illumination and a NIR diode-array detector with a nominal wavelength range of 1100-2100 nm with approximately 5 nm wavelength spacing. The integration time was 11 ms with 100 spectral co-adds. The Raman spectrometer and probe were a RamanRxn2 analyzer (Kaiser Optical Systems, Inc, Ann Harbor, MI) equipped with a 3 mm focusing lens on a PhAT probe. The nominal wavenumber For these cases, data were generated solely to excite the API signal in the mixture. This is achieved by first operating at nominal conditions and introducing a step change in concentration by turning the API feeder set-point to zero, while one of the major diluents is used to compensate mass flow and maintain throughput.
Product A: IOT vs. EIOT on NIR spectra
The case study on "Product A" is used here for a comparison between IOT and EIOT and illustrate the advantages of estimatingŜ 0 (instead of measuring S as proposed in IOT 22 ). Data were collected on two different mass throughputs, composed of 20 spectra representative of the nominal blend and 20 spectra representative of the placebo blend. Pure component spectra were available for this case and were used as S n in Eq.1 for the case of IOT. It was observed that the use of IOT resulted in a biased concentration estimate on the nominal blends (Figure 5a ). This was attributed to the impact of Figure 5 . (a) Estimated mass fraction for API-A using IOT, (b) Pure spectrum for API and excipient and spectra collected during a step change.
[Color figure can be viewed at wileyonlinelibrary.com] Figure 6 . Performance of EIOT on "Product A," (a) measured pure component spectrum and estimated apparent pure spectrum (b) estimated apparent pure spectrum for API and excipient and measured spectrum during step change (c) estimated mass fraction for API-A with and without bilinear term and (d) residual spectra.
scattering phenomena on NIR spectra, which in turn makes the mixture spectra potentially deviate from Beer-Lambert's law potentially because the pathlength becomes a function of many factors including wavelength. 27, 28 The spectral intensity of a sample blend at certain wavelength regions (after standard normal variance [SNV] correction) was observed to be between that of API and placebo spectra. At the same time, for some other spectral regions, the mixture spectra was observed to fall out of the envelope composed by placebo and the pure API spectra. This effect results in nonfeasible solutions to the IOT formulation as the basic relationship between mixture spectra and pure is not followed.
For the case of EIOT, the spectra acquired at steady-state before and after the step change experiment were used to estimate the pure component spectra of API-A and one of the major diluents (Microcrystalline Cellulose [MCC]). As seen in Figure 6a , the estimated pure spectraðS 0 Þ for both components showed good resemblance with measure pure spectra, such as the triplet observed in 1600-1800 nm for API-A and the broad band in 1400-1600 nm for the diluent. The measured spectra in Figure 6a were offset for clarity of the graphic.
Overlaying the data collected from the step change with the estimated spectra for each pure species (Figure 6b) , it can be seen that the spectral intensity variation of the step change data (across the entire wavelength regions after SNV pretreatment) lies between the estimated spectrum (Ŝ 0 Þ of the API-A and the major excipient. By using informative data, a simple least squares approach (Eq. 8) was capable of extracting the chemical signatures of the species whose concentration was excited in the experiment.
After the chemically relevant portion of D M was estimated (Ŝ 0 Þ, its effect was removed from the spectra (Eq.9) resulting in what we refer to as the "nonchemical interferences" portion of D M (Figure 1, left) . An averaged spectrum of a subset of observations (black line, Figure 1, right) was defined as the s I vector representing the spectral structure of the nonchemical interference. After these two steps, the estimated mass fraction of API-A was found to have improved accuracy with respect to the observed ones (Figure 6c) , with improved accuracy compared to that without using s I . This illustrates the value of extending the IOT method (hence EIOT), using a simple bilinear term r I s I to take the potential nonchemical interferences in the sample into consideration. After using s I as the augmentation vector, the deflated residual spectra were also found to fluctuate closer to 0 (Figure 6d ).
Product A: EIOT's performance during a step change
Results obtained with EIOT were contrasted with results from a PLS model for spectra acquired during a step change. Both results are converted to percent of nominal concentration for the drug product (%). The method calibration for "Product A" by the PLS approach was reported elsewhere. 11 In brief, a supersaturated design via Nearly Orthogonal Arrays was used to generate a 10-blend DOE and calibration spectra from these blends were collected on an offline device to conserve the total amount of API used in the calibration. In total, about 5 kg of API was used for this method calibration. As can be in Figure 7 , the performance of PLS and EIOT was comparable at steady-state operation, despite the considerable difference on the requirement for training data. In addition, as the original PLS model was built from 80% to 110% label claim, it was not intended to predict spectral collected on placebo blends. Therefore, placebo spectra were added to the original DOE dataset to build a PLS model Figure 7 . EIOT performance on an entire step change of "Product A."
[Color figure can be viewed at wileyonlinelibrary.com] Figure 8 . Performance of two EIOT models (built with two different spectrometers) on "Product P" using spectra acquired with "Manufacturing Spectrometer."
[Color figure can be viewed at wileyonlinelibrary.com]
spanning from 0% to 110% label claim for comparison here.
As can be seen in the magnified insert in the figure, both PLS models had difficulty accurately predicting the API concentration from the placebo spectra. In comparison, EIOT was able to accurately predict the API concentration in placebo spectra This accuracy is attributed to the effect of the constraint in Eq.5. Having a predicted concentration that follows the expected behavior of a mass fraction (nonnegative between 0 and 1) allows the straightforward use of such predictions to estimate the parameters from a deterministic model of the system. 10 Although both PLS and EIOT were found to estimate API concentration equivalently well during steady-state operation, it is worth pointing out the different levels of effort required to establish the two models. The PLS model required significantly more effort than EIOT, as it consumes the time and resources necessary (e.g., personnel and material) to generate a representative calibration set based upon the aforementioned 5 kg of API and 10-blend DOE, despite the use of offline device to conserve the amount of API used. 11 However, EIOT only required two sets of nominal and placebo blends at two dose strengths, which does not require additional consumption of API other than steady-state operation. This very lean development effort required by EIOT makes it an attractive alternative for early stages of pharmaceutical process development and clinical manufacture when supply for API material is limited.
Product P: EIOT's Performance across instruments
Two EIOT methods were developed for "Product P" using step change data collected on a development spectrometer as well as in a manufacturing spectrometer. The performance of both methods on an independent run using the manufacturing spectrometer are presented in Figure 8 in terms of percent of nominal concentration for the drug product (%).The EIOT method across spectrometers performed as well as that within spectrometer (Figure 8a ). The offline HPLC values collected on the tablets throughout the run also confirmed that. The residual spectra by EIOT (blue spectrum in Figure 8b ) matched well with the differential spectrum calculated between two spectrometers on the nominal blend (black spectrum in Figure 8b ). This leads us to conclude that: by using an optimization approach EIOT is capable of decoupling the chemical signal from nonchemical interference (i.e., spectrometer difference in this case). This capability of EIOT is expected to reduce the cost of ownership by avoiding the typical calibration transfer effort when transferring a method across sites/ spectrometers.
Product B: EIOT on Raman spectra
EIOT was also evaluated on Raman spectra collected during the development of "Product B," a low dose product. In Figure 9a , the estimated pure component spectraðS 0 Þ of the API-B and the major diluent (lactose) were found to consist of similar peak locations compared to the measured ones. It is worthy pointing out thatŜ 0 for both API-B and the diluent contained a slope background, which was attributed to the fluorescence background caused by another diluent in the formula. Given theŜ 0 , the concentration estimates of both API-B were found to be consistent with the observed values ( Figure 9b ). For this case study, the augmentation term for nonchemical interferences was determined to not be necessary as the predictions with and without this term were very similar, leaving a residual with no visible structure (Figure 9c ).
Application of EIOT in Early Stages of Pharmaceutical Development
The EIOT method was applied in the development of a new drug product that required tablets of four dose strengths (I, II, III, and IV) to be manufactured to supply clinical studies. Spectra were collected for the first batch, using nominal and placebo formulations in a continuous direct compression line, these data were used to estimate the parameters for EIOT. The resulting EIOT parameters were used to monitor the real-time estimates for concentration of drug in the following 11 batches. The complete campaign included two different mass flows and three different turret speeds in the tablet press as indicated in Table 2 . The root means squared error of prediction (RMSEP) against laboratory results from physical samples analyzed by high-performance liquid chromatography (HPLC) are shown in Table 2 , along with the average bias and the standard deviation of the predictions during the collection phase of the batch. The overall root mean squared error of prediction (RMSEP) and bias for most batches was mostly within 1% to 2%, with the exception of two batches, where the predictions did exhibit RMSEP and bias of greater quantities. The exhibited performance of the method is deemed acceptable and comparable with our experience using a PLS approach. However, the EIOT approach required significantly less investment in the development of the model and also seemed more robust to process differences than the PLS approach.
It is important to emphasize that the data we have collected so far in the application of EIOT suggests a similar, but not necessarily superior, performance to PLS. Figure 10 illustrates a summary of the performance of EIOT for another product, where four different doses were manufactured. In this figure, each box represents the 25th and 75th percentile of samples. The boxes contrast the performance of a PLS model that was fitted using a complete experimental design (as discussed in Hetrick et al. 11 ) with the EIOT model trained with data from two batches, at two concentration levels. As shown in Figure 10 , the overall bias from laboratory results (obtained using HPLC) and the standard deviation at steady state for EIOT and PLS are comparable and no method is (in this case) particularly superior to the other. Here, the EIOT model performed at a level similar to the PLS model even though it had a much leaner training data set. Data from a total of 12 batches were used to produce Figure 10 . A well-know advantage of spectroscopic methods is the ability to obtain an estimate of composition at a much faster frequency than that achievable with physical sampling. With EIOT, we suggest that the practitioner can utilize this tool fairly early in the pharmaceutical development cycle. Figure 11 illustrates this, as the drug content predictions obtained with EIOT were able to detect an oscillation in the concentration of drug in the tablet-press feed frame that resulted in a deviation, which would not have been detected by physical sampling. Implementing the EIOT calculations in real-time allowed the detection and identification noncompliant product, which was rejected accordingly to the quality protocols established in the manufacturing site.
EIOT Diagnostics
A unique feature of the PLS method is that of capturing the covariance structure of the regressor (X) as well as the response (Y). 29 This enables PLS to diagnose when a new observation of the regressor differs in its original correlation structure from the training data. The Hotelling's T 2 and the squared prediction error (spe) are typically used to monitor the performance of a multivariate model and determine the adequacy of the current model parameters and eventually decide if the model needs to be updated or not. 30 These two diagnostics are complementary to each other, as one is a global diagnostic of distance within the model plane (Hotelling's T 2 ), while the other is a global diagnostic of orthogonal distance from the model plane (spe).
EIOT is not a reduced rank approach where data are projected down to a subdimensional fixed plane. Consequently, the diagnostics from PLS do not translate in a straightforward manner. In the EIOT equation that describes a new observation (Eq. 13 derived from Eq. 12) there are three quantities being estimated in real-time: the vector of mass fraction for the species in the sample (r), the strength of the non-chemical interferences (r I ) and the global error (ε). The vector (r) is the primary information of interest; however, this quantity is bounded by a hard constraint to assure the summation of the elements of r n to unity. This constraint prevents by definition the excursion of any element of r n outside of the range of 0 to 1; it is assumed that at least one of these elements (the one corresponding to the mass fraction of drug) will be continuously monitored by default. The remaining two quantities (r I and ε) are unbounded. The error vector, that can be summarized by the summation of the squares (Eq. 14), translating it into a scalar, we refer to as the squared spectral residual term (ssr). 
Similar to PLS, we propose two real-time diagnostics to monitor the adequacy of an EIOT set of parameters for a given system. We propose to use the strength of nonchemical interference (r I ) as a within model diagnostic; and the squared spectral residual (ssr) as a diagnostic of orthogonal distance from the model. We postulate that monitoring the r I term will enable the assessment on whether the strength of nonchemical interferences for the current sample remains within the range observed before; the ssr on the other hand serves a metric of model mismatch that may serve to determine if the signature of the nonchemical interferences needs to be updated.
Current experience has shown, that the r I appears to follow a normal distribution around the mean value for a given campaign ( Figure 12) ; Additionally, the mean value for r I seems to differ from one campaign to the next. This behavior indicates the need for a within-campaign and campaign-to-campaign approach to monitor the behavior of the r I .
The ssr on the other hand, being a summation of squares and thus all positive numbers, can be approximated by a Weibull distribution. At this point in our research we do not have enough data to propose the necessary statistics to describe these figures. Model diagnostics and the long-term maintenance of the EIOT parameters remain a subject of research and a focus of a following publication.
Concluding Remarks
In this work, we propose to extend the IOT method in order to address the deviations from Beer-Lambert's law and the presence of interferences of non-chemical nature. This extension consists of: (a) the estimation of the apparent pure component spectra from data of known concentration, and (b) a simple augmentation with a bilinear term meant to capture the structure and the strength of the nonchemical interferences on sample spectra. The EIOT method appears to effectively decompose the information in new samples of spectra into their chemical information and the nonchemical interferences thus providing the method with enhanced robustness when transferred from one instrument to the other, and with acceptable performance in the presence of physical variations not explicitly included in the training data set. The overall performance of EIOT compared to a PLS model built with a much richer and larger data set is comparable. The lean requirements to determine the parameters of an EIOT model positions the method as an attractive alternative in early stages of development, enabling the practitioner to take advantage of a functional PAT solution in these early stages. The overall reduction in data needed and agility obtained results in lower costs and potentially in accelerated timelines for the development of a new drug product. Model diagnostics and long-term maintenance remain a subject of research and a focus of a following publication.
